When do you consider cytoreduction in patients with Essential Thrombocytosis?

In a patient with no evidence of bleeding, do you use a platelet cutoff? Do you utilize genomic testing (eg CALR, MPL, JAK2, etc.) to decide on cytoreduction?

Answer from: Medical Oncologist at Academic Institution

I consider cytoreduction for patients with ET if they are at high risk of thrombosis based on the R-IPSET score. For intermediate risk patients, I factor in medical comorbidities and symptoms to help decide to initiate therapy. I don't start cytoreduction based on a platelet count alone. If a patien...

Comments

Medical Oncologist at Allina Health Cancer Institute
Thank you, this is very helpful.

Medical Oncologist at St. Francis Hospital
Thanks. What would you do in a low-risk, late 40s...

Medical Oncologist at Rush University Medical Center
Thank you. If a patient has concomitant CALR type ...

Please select the option that best describes you:

When do you consider cytoreduction in patients with Essential Thrombocytosis?

Related Questions